By Connor Hart
Shares of Ikena Oncology jumped after the company said it would merge with Inmagene Biopharmaceuticals.
The stock rose 15%, to $1.79, in midday trading Monday. Shares are down 9% since the beginning of the year.
The Boston biotech company said the merger is expected to result in $175 million to support further development of IMG-007, Inmagene's potential treatment for atopic dermatitis, also known as eczema. This figure includes proceeds from a $75 million private placement the companies will launch.
Upon closing, which is expected in mid-2025, Ikena stockholders will own about 34.8% of the combined company. Inmagene equity holders will have a roughly 43.5% stake, while financing investors will own about 21.7%.
The combined company plans to operate under the name ImageneBio and trade on NASDAQ under the ticker "IMA". A formal search for the chief executive officer of the combined company has been initiated, the companies said.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
December 23, 2024 11:35 ET (16:35 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.